|Videos|June 12, 2019

Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Newsletter

Related Content

European Commission Approves Tovorafenib in BRAF+ Pediatric Low-Grade Glioma

FDA Grants Fast Track Designation to Daretabart for High-Risk Neuroblastoma

FDA Accepts NDA for Imaging Agent TLX101-Px in Brain Cancer

FDA Grants ODD to Rhenium-186 Obisbemeda for Pediatric Malignant Glioma

Plixorafenib Receives FDA BTD for BRAF V600E–Mutated High-Grade Glioma

Latest CME

19th Annual New York GU Cancers Congress®

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breaking Down the Rationale for Targeting TROP2 in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Cross-Disease Integration of Immunotherapy Innovations

Optimizing Treatment for Biliary Tract Cancers

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Arizona Clinical Oncology Society

Missouri Oncology Society

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Go to PER in Chicago

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Radioligand Therapy 101: The Science Behind the Strategy

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Trending on CancerNetwork

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer